STE
STERIS plc
STE's fundamentals are strong and it looks cheap: trading at 30x earnings, below its usual 40x. Analysts expect earnings growth.
STE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
STE's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
STE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 22x | $253 | — |
| Current | 30x | $253 | — |
| Cheap | 33x | $279 | +9.9% |
| Fair | 40x | $336 | +33% |
| Expensive | 80x | $677 | +167% |
Historical ranges are pointers, not guarantees.
STE's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 22x next year's earnings.
STE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for STE, with profitability improving.
STE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.78 | +40% |
| Q3 2026 | $8.43 | +21% |
| Q2 2026 | $8.18 | +25% |
| Q1 2026 | $7.93 | +28% |
| Q4 2025 | $7.17 | +52% |
| Q3 2025 | $6.96 | +59% |
| Q2 2025 | $6.53 | +62% |
| Q1 2025 | $6.20 | +62% |
| Q4 2024 | $4.71 | -18% |
STE earned $8.43 per share over the past year, up 21% from the year before.
STE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +8.8% |
| Q2 2026 | $1.5B | +7.3% |
| Q1 2026 | $1.6B | +7.3% |
| Q4 2025 | $1.5B | +9.2% |
| Q3 2025 | $1.5B | +9.9% |
| Q2 2025 | $1.4B | +8.7% |
| Q1 2025 | $1.5B | +4.3% |
| Q4 2024 | $1.4B | -1.8% |
STE's revenue has grown year over year for seven quarters in a row: $1.6B last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.3 points |
| Q2 2026 | 19% | +1.5 points |
| Q1 2026 | 20% | +5.3 points |
| Q4 2025 | 18% | +0.4 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 18% | +3.2 points |
| Q1 2025 | 15% | -2.7 points |
| Q4 2024 | 18% | +2.4 points |
STE's operating margin was 19% last quarter, about level with the same quarter a year ago.
STE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $212.9M | +5.8% |
| Q2 2026 | $279.6M | -14% |
| Q1 2026 | $245.2M | +29% |
| Q4 2025 | $199.5M | -18% |
| Q3 2025 | $201.3M | +35% |
| Q2 2025 | $326.4M | +67% |
| Q1 2025 | $189.9M | +16% |
| Q4 2024 | $243.6M | +41% |
STE's free cash flow has been positive every quarter for seven years: $937M over the past year, down 2.5% from the year before.
STE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -300K shares |
| 1 year | -1.2% | -1.2M shares |
| 3 years | -1.8% | -1.8M shares |
| 5 years | -3.1% | -3.1M shares |
| Available history | +14% | +12M shares |
STE has 98M diluted shares, down 1.2% from a year ago, with $340M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $115.5M |
| Q1 2026 | $74.3M |
| Q4 2025 | $50.1M |
| Q3 2025 | $100.5M |
| Q2 2025 | $10.6M |
| Q1 2025 | $263,000 |
| Q4 2024 | $100.4M |
STE spent $340M buying back its own shares over the past year, up 61% from the year before.
STE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.5x | Healthy |
STE's net debt is less than a year of its operating earnings (EBITDA), down from 1.1 years a year ago.
STE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 79.9 | Neutral |
STE's weekly RSI is 65 (neutral) and its Stochastic is 80 (neutral).
STE PE vs Healthcare Sector
| Metric | STE | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 10 | 29 | 19 pts below |
STE is trading at 30x earnings, a 16% premium to the Healthcare sector's median of 26x.
STE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $227.4 | 11% above |
| 20 week MA | $224.8 | 13% above |
| 50 week MA | $230.0 | 10% above |
| 100 week MA | $231.6 | 9.4% above |
| 200 week MA | $224.2 | 13% above |
STE is in an uptrend: it's above all five of its weekly moving averages, and 13% above its 200-week average.
STE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $151.8 | $186.2 | +23% |
| 2021 | $186.2 | $241.1 | +29% |
| 2022 | $241.1 | $182.1 | -24% |
| 2023 | $182.1 | $219.9 | +21% |
| 2024 | $219.9 | $208.0 | -5.4% |
| 2025 | $208.0 | $255.4 | +23% |
| 2026 YTD | $255.4 | $253.4 | -0.8% |
STE has finished higher in four of the last six years. It's down 0.8% so far in 2026.